NAICONS Srl, founded in late 2013 by twelve individuals previously involved in similar initiatives, was established with the objective of commercializing a series of assets related to microorganisms and the many molecules they produce.
The incorporation of NAICONS Srl was de facto a repositioning to a for-profit organization of New Anti-Infectives Consortium Scrl, a not-for-profit organization with a complex shareholder structure set up in late 2006 with the objective of acquiring assets (among others, the strain collection and a few patents) that were present in the Biosearch Italia/Vicuron drug discovery center located in Gerenzano, Italy, just NW of Milan.
Many of NAICONS Srl founders were actually founders, shareholders and/or key figures of Biosearch Italia, a company set up in 1996 as a spinoff of the Lepetit Research Center - at that time owned by Hoechst Marion Roussel, then a big pharma company, now part of Sanofi. Biosearch Italia was the first Italian biotech company to be publicly listed in the Italian stock exchange in 2000 and, after its merger with a similarly-sized American company in 2003, had a dual listing in Nasdaq and in Nuovo Mercato as Vicuron.
In 2005, Pfizer acquired Vicuron for its late-stage antibiotics for 1.9 B$, and the assets mentioned before had become available for bidders when Pfizer decided to close the research facilities in Gerenzano. Those acquired assets, plus others discovered and developed since 2006, represent the key elements of NAICONS technology platform.
Today Naicons is developing micro4all, the first Search-and-Order Molecules Engine available through an online subscription that is going to redefine the whole Drug Discovery Process.